Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BACKGROUND: While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood. We exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiniwa, Yukiko, Nakamura, Kenta, Mikoshiba, Asuka, Ashida, Atsuko, Akiyama, Yasuyuki, Morimoto, Atsushi, Okuyama, Ryuhei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968258/
https://www.ncbi.nlm.nih.gov/pubmed/33731038
http://dx.doi.org/10.1186/s12885-021-08016-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968258/
https://www.ncbi.nlm.nih.gov/pubmed/33731038
http://dx.doi.org/10.1186/s12885-021-08016-y

Ejemplares similares